Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of GAAP Ofteno versus Xalatan in open-angle glaucoma or ocular hypertension
2010-021456-25Phase 3Active
- Sponsor
- Laboratorios Sophia
- Start
- Sep 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of latanoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Laboratorios Sophia. Primary endpoint: Primary safety variables. Started Sep 2010; status: active.
02
Drugs
latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2010-021456-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021456-25.